Y90 -Ibritumomabtiuxetan (Zevalin)Approved in US 2002  Biogen IDECPharmaceuticals CorpType ImAb  Murine IgG1κ  Zevalin (54 patients of Rituximab refractory FL, ORR 74%) [83,84]Zevalin vs Rituximab, randomized multicenter study (143 patients ofRelapsed or refractory FL, ORR 80 vs 56%) [84,85]  High CDCLow ADCC